Cargando…

Bortezomib in mantle cell lymphoma: comparative therapeutic outcomes

Mantle cell lymphoma (MCL) is an incurable, typically aggressive subtype of non-Hodgkin lymphoma, accounting for 4%–7% of newly diagnosed non-Hodgkin lymphoma cases. Chemoresistance commonly ensues in MCL, and patients with this heterogeneous disease invariably relapse, underscoring the unmet need f...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vallumsetla, Nishanth, Paludo, Jonas, Kapoor, Prashant
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2015
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4644179/ https://www.ncbi.nlm.nih.gov/pubmed/26609233 http://dx.doi.org/10.2147/TCRM.S72943

Ejemplares similares

Arsenic trioxide rewires mantle cell lymphoma response to bortezomib
por: Zhao, Ling-Ling, et al.
Publicado: (2015)

The effect of Bortezomib and Rapamycin on Telomerase Activity in Mantle Cell Lymphoma
por: Uziel, Orit, et al.
Publicado: (2014)

Harnessing Noxa demethylation to overcome Bortezomib resistance in mantle cell lymphoma
por: Leshchenko, Violetta V., et al.
Publicado: (2015)

Inhibition of Lyn is a promising treatment for mantle cell lymphoma with bortezomib resistance
por: Kim, Areumnuri, et al.
Publicado: (2015)

Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma
por: Yang, David T, et al.
Publicado: (2008)

Clinical characteristics and outcomes of primary versus secondary gastrointestinal mantle cell lymphoma
por: Castellino, Alessia, et al.
Publicado: (2021)

3-Methyladenine but not antioxidants to overcome BACH2-mediated bortezomib resistance in mantle cell lymphoma
por: Feng, Min, et al.
Publicado: (2021)

Evolving frontline immunochemotherapy for mantle cell lymphoma and the impact on survival outcomes
por: Castellino, Alessia, et al.
Publicado: (2022)

Synergistic suppression of the PI3K inhibitor CAL-101 with bortezomib on mantle cell lymphoma growth
por: Qu, Fu-Lian, et al.
Publicado: (2015)

Bortezomib-based therapy for transplant-ineligible East Asian patients with newly diagnosed mantle-cell lymphoma
por: Jin, Jie, et al.
Publicado: (2018)

Effects of the Proteasome Inhibitor Bortezomib in Combination with Chemotherapy for the Treatment of Mantle Cell Lymphoma: A Meta-analysis
por: Li, Shi-Jun, et al.
Publicado: (2020)

PB2297: PHASE II STUDY OF BORTEZOMIB, CYTARABINE, AND DEXAMETHASONE IN RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA
por: Shin, Junghoon, et al.
Publicado: (2023)

Smoldering mantle cell lymphoma
por: Ye, Haige, et al.
Publicado: (2017)

Therapeutic Activity of Lenalidomide in Mantle Cell Lymphoma and Indolent Non-Hodgkin's Lymphomas
por: Gunnellini, Marco, et al.
Publicado: (2012)

P1096: TREATMENT PATTERNS AND OUTCOMES IN RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA
por: Bock, A., et al.
Publicado: (2022)

Circulating tumor DNA predicts therapeutic outcome in mantle cell lymphoma
por: Lakhotia, Rahul, et al.
Publicado: (2022)

The effectiveness and harms of bortezomib in combination with chemotherapy for mantle cell lymphoma: A protocol for systematic review and meta-analysis
por: Wang, Xiaoxia, et al.
Publicado: (2020)

Emerging therapies in mantle cell lymphoma
por: Hanel, Walter, et al.
Publicado: (2020)

Bcl-2 Family Members Bcl-xL and Bax Cooperatively Contribute to Bortezomib Resistance in Mantle Cell Lymphoma
por: Luanpitpong, Sudjit, et al.
Publicado: (2022)

Evaluation of Bortezomib-BeEAM (2BeEAM) as Chemotherapy Regimen Prior to ASCT in Patients with Mantle Cell Lymphoma
por: Huwyler, Fabrizio, et al.
Publicado: (2023)

Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agents
por: Inamdar, Arati A., et al.
Publicado: (2016)

Time to progression of disease and outcomes with second-line BTK inhibitors in relapsed/refractory mantle cell lymphoma
por: Villa, Diego, et al.
Publicado: (2023)

A phase 2 study of rituximab, bendamustine, bortezomib and dexamethasone for first-line treatment of older patients with mantle cell lymphoma
por: Gressin, Rémy, et al.
Publicado: (2019)

Management of mantle cell lymphoma in the elderly patient
por: Doorduijn, Jeanette K, et al.
Publicado: (2013)

Current overview and treatment of mantle cell lymphoma
por: Schieber, Michael, et al.
Publicado: (2018)

Management of Drug Resistance in Mantle Cell Lymphoma
por: Roué, Gaël, et al.
Publicado: (2020)

CAR T-Cell therapy for the management of mantle cell lymphoma
por: Huang, Zoufang, et al.
Publicado: (2023)

Evolving treatment patterns and improved outcomes in relapsed/refractory mantle cell lymphoma: a prospective cohort study
por: Bock, Allison M., et al.
Publicado: (2023)

RECOGNITION OF A TRACHEOESOPHAGEAL FISTULA IN A MECHANICALLY VENTILATED PATIENT
por: Vallumsetla, Nishanth, et al.
Publicado: (2020)

Cyclin D1-CDK4 activity drives sensitivity to bortezomib in mantle cell lymphoma by blocking autophagy-mediated proteolysis of NOXA
por: Heine, Simon, et al.
Publicado: (2018)

Bortezomib enhances the anti-cancer effect of the novel Bruton’s tyrosine kinase inhibitor (BGB-3111) in mantle cell lymphoma expressing BTK
por: Wang, Xianhuo, et al.
Publicado: (2021)

Evaluating the Therapeutic Potential of Zanubrutinib in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma: Evidence to Date
por: Sawalha, Yazeed, et al.
Publicado: (2020)

Constitutive Activation of p62/Sequestosome-1-Mediated Proteaphagy Regulates Proteolysis and Impairs Cell Death in Bortezomib-Resistant Mantle Cell Lymphoma
por: Quinet, Grégoire, et al.
Publicado: (2022)

Temsirolimus in the treatment of relapsed or refractory mantle cell lymphoma
por: Samad, Nousheen, et al.
Publicado: (2010)

Temsirolimus in the treatment of relapsed and/or refractory mantle cell lymphoma
por: Galimberti, S, et al.
Publicado: (2010)

Current trials for frontline therapy of mantle cell lymphoma
por: Steiner, Raphael E., et al.
Publicado: (2018)

Progress in molecular feature of smoldering mantle cell lymphoma
por: Jiang, Panruo, et al.
Publicado: (2021)

Role of DNA methylation in renal cell carcinoma
por: Shenoy, Niraj, et al.
Publicado: (2015)

The clinical features, therapeutic responses, and prognosis of the patients with mantle cell lymphoma
por: Ying, Zhi-Tao, et al.
Publicado: (2012)

Rac1 is a novel therapeutic target in mantle cell lymphoma
por: Tian, Tian, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_j58snglhfec5rackgdajvlcfh3